Earnings summaries and quarterly performance for Context Therapeutics.
Executive leadership at Context Therapeutics.
Board of directors at Context Therapeutics.
Research analysts covering Context Therapeutics.
Recent press releases and 8-K filings for CNTX.
Context Therapeutics Inc. Updates Corporate Presentation with Pipeline Milestones and Cash Runway
CNTX
New Projects/Investments
- Context Therapeutics Inc. updated its corporate presentation on January 8, 2026, outlining its strategy to develop T cell Engagers (TCE) for solid tumors.
- The company's pipeline includes three bispecific antibodies: CTIM-76 (Claudin 6 x CD3), CT-95 (Mesothelin x CD3), and CT-202 (Nectin-4 x CD3).
- Key anticipated milestones include updated interim Ph 1a data and Ph 1b dose selection for CTIM-76 in Q2 2026, initial Ph 1a data for CT-95 in Mid 2026, and submission of regulatory filings for a first-in-human trial for CT-202 in Q2 2026.
- Context Therapeutics Inc. reports a strong financial position with an expected cash runway into 2027.
Jan 8, 2026, 12:43 PM
Kardigan Provides 2026 Corporate Update and Announces J.P. Morgan Healthcare Conference Participation
CNTX
Management Change
New Projects/Investments
Guidance Update
- Kardigan is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, and anticipates clinical data readouts in 2026 for its three late-stage programs addressing dilated cardiomyopathy, hypertension, and calcific aortic valve stenosis.
- Andy Pasternak has been appointed as the new Chief Strategy Officer, bringing extensive leadership in biopharmaceutical business development and company growth.
- In 2025, Kardigan secured $300 million in Series A funding and an additional $254 million in Series B funding, acquired Prolaio, and initiated three late-stage clinical trials.
- The company also presented positive Phase 2 data for danicamtiv (for genetic DCM) and ataciguat (for CAVS) in 2025.
Jan 6, 2026, 2:00 PM
Context Therapeutics Reports Q3 2025 Financial and Clinical Results
CNTX
Earnings
Guidance Update
New Projects/Investments
- Context Therapeutics reported cash and cash equivalents of $76.9 million as of September 30, 2025, with an expected cash runway into 2027. The company also reported a net loss of $9.7 million for the third quarter of 2025.
- In its CTIM-76 Phase 1 trial, 12 patients were enrolled as of October 30, 2025, showing preliminary signs of anti-tumor activity and a favorable safety profile with no Cytokine Release Syndrome greater than Grade 1 observed.
- The company anticipates providing updated interim Phase 1a data for CTIM-76 and Phase 1b dose selection in Q2 2026, initial Phase 1a data for CT-95 in mid-2026, and completing regulatory filings for a first-in-human trial for CT-202 in Q2 2026.
Nov 5, 2025, 9:21 PM
Context Therapeutics Reports Third Quarter 2025 Financial and Clinical Results
CNTX
Earnings
Guidance Update
New Projects/Investments
- Context Therapeutics reported cash and cash equivalents of $76.9 million as of September 30, 2025, and expects this to fund operations into 2027.
- The company posted a net loss of $9.7 million for the third quarter of 2025.
- The ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) shows encouraging antitumor activity and safety, with updated interim Phase 1a data and Phase 1b dose selection anticipated in the second quarter of 2026.
- The Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels, with initial Phase 1a data expected in the middle of 2026.
- For CT-202 (Nectin-4 x CD3), Context expects to complete necessary regulatory filings to support the initiation of a first-in-human trial in the second quarter of 2026.
Nov 5, 2025, 9:15 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more